Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Moderna Inc 325 BINNEY STREET CAMBRIDGE MA 02142 USA

www.modernatx.com Employees: 5,800 P: 617-714-6500

Sector:

Medical

Description:

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Key Statistics

Overview:

Market Capitalization, $K 19,419,480
Enterprise Value, $K 17,414,480
Shares Outstanding, K 390,734
Float, K 348,144
% Float 89.10%
Short Interest, K 71,506
Short Float 18.30%
Days to Cover 4.54
Short Volume Ratio 0.63
% of Insider Shareholders 10.90%
% of Institutional Shareholders 75.33%

Financials:

Annual Sales, $ 1,944 M
Annual Net Income, $ -2,822 M
Last Quarter Sales, $ 678,000 K
Last Quarter Net Income, $ -826,000 K
EBIT, $ -3,074 M
EBITDA, $ -2,926 M

Growth:

1-Year Return 46.99%
3-Year Return -64.31%
5-Year Return -67.90%
5-Year Revenue Growth 141.97%
5-Year Earnings Growth -270.41%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -2.11 on 02/13/26
Next Earnings Date 05/07/26
Earnings Per Share ttm -7.27
EPS Growth vs. Prev Qtr -313.73%
EPS Growth vs. Prev Year 15.60%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

MRNA Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -30.15%
Return-on-Assets % -22.95%
Profit Margin % -145.16%
Debt/Equity 0.07
Price/Sales 9.37
Price/Cash Flow N/A
Price/Book 1.98
Book Value/Share 22.14
Interest Coverage -1.72
60-Month Beta 1.32
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar